From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics Article Swipe
Akash Roy
,
Valina L. Dawson
,
Ted M. Dawson
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.neurot.2025.e00712
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.neurot.2025.e00712
GLP-1 receptor agonists (GLP-1RAs), initially approved for diabetes and obesity, are now under investigation for neuroprotective effects in a range of neurological disorders. These agents, whose receptors are widely expressed in brain regions involved in cognition and metabolism, modulate neurotransmitter release and promote neurogenesis. While preclinical studies consistently demonstrate benefits in models of Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), clinical trial outcomes have been variable, largely owing to heterogeneity in study populations and trial design. Newer agents, such as NLY01 and tirzepatide, are under development to enhance central nervous system penetration and efficacy. Although GLP-1RAs are generally safe in metabolic conditions, their use in neurological diseases requires careful monitoring and patient selection. Future directions include developing reliable biomarkers, implementing precision medicine strategies, and exploring the use of combination therapies to maximize therapeutic potential.
Related Topics
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.neurot.2025.e00712
- https://www.neurotherapeuticsjournal.org/article/S1878-7479(25)00190-4/pdf
- OA Status
- gold
- Cited By
- 5
- References
- 66
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4412723339
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4412723339Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.neurot.2025.e00712Digital Object Identifier
- Title
-
From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeuticsWork title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-07-29Full publication date if available
- Authors
-
Akash Roy, Valina L. Dawson, Ted M. DawsonList of authors in order
- Landing page
-
https://doi.org/10.1016/j.neurot.2025.e00712Publisher landing page
- PDF URL
-
https://www.neurotherapeuticsjournal.org/article/S1878-7479(25)00190-4/pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.neurotherapeuticsjournal.org/article/S1878-7479(25)00190-4/pdfDirect OA link when available
- Concepts
-
Neurology, Neuroscience, Metabolism, Receptor, Chemistry, Biology, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
5Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 5Per-year citation counts (last 5 years)
- References (count)
-
66Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4412723339 |
|---|---|
| doi | https://doi.org/10.1016/j.neurot.2025.e00712 |
| ids.doi | https://doi.org/10.1016/j.neurot.2025.e00712 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40738791 |
| ids.openalex | https://openalex.org/W4412723339 |
| fwci | 22.87559287 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D000818 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Animals |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D000097789 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Glucagon-Like Peptide-1 Receptor Agonists |
| mesh[3].qualifier_ui | Q000378 |
| mesh[3].descriptor_ui | D000067757 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | metabolism |
| mesh[3].descriptor_name | Glucagon-Like Peptide-1 Receptor |
| mesh[4].qualifier_ui | Q000627 |
| mesh[4].descriptor_ui | D018696 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | therapeutic use |
| mesh[4].descriptor_name | Neuroprotective Agents |
| mesh[5].qualifier_ui | Q000494 |
| mesh[5].descriptor_ui | D018696 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | pharmacology |
| mesh[5].descriptor_name | Neuroprotective Agents |
| mesh[6].qualifier_ui | Q000188 |
| mesh[6].descriptor_ui | D009422 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | drug therapy |
| mesh[6].descriptor_name | Nervous System Diseases |
| mesh[7].qualifier_ui | Q000378 |
| mesh[7].descriptor_ui | D009422 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | metabolism |
| mesh[7].descriptor_name | Nervous System Diseases |
| mesh[8].qualifier_ui | Q000187 |
| mesh[8].descriptor_ui | D001921 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | drug effects |
| mesh[8].descriptor_name | Brain |
| mesh[9].qualifier_ui | Q000378 |
| mesh[9].descriptor_ui | D001921 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | metabolism |
| mesh[9].descriptor_name | Brain |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D006801 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Humans |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D000818 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Animals |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000097789 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Glucagon-Like Peptide-1 Receptor Agonists |
| mesh[13].qualifier_ui | Q000378 |
| mesh[13].descriptor_ui | D000067757 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | metabolism |
| mesh[13].descriptor_name | Glucagon-Like Peptide-1 Receptor |
| mesh[14].qualifier_ui | Q000627 |
| mesh[14].descriptor_ui | D018696 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | therapeutic use |
| mesh[14].descriptor_name | Neuroprotective Agents |
| mesh[15].qualifier_ui | Q000494 |
| mesh[15].descriptor_ui | D018696 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | pharmacology |
| mesh[15].descriptor_name | Neuroprotective Agents |
| mesh[16].qualifier_ui | Q000188 |
| mesh[16].descriptor_ui | D009422 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | drug therapy |
| mesh[16].descriptor_name | Nervous System Diseases |
| mesh[17].qualifier_ui | Q000378 |
| mesh[17].descriptor_ui | D009422 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | metabolism |
| mesh[17].descriptor_name | Nervous System Diseases |
| mesh[18].qualifier_ui | Q000187 |
| mesh[18].descriptor_ui | D001921 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | drug effects |
| mesh[18].descriptor_name | Brain |
| mesh[19].qualifier_ui | Q000378 |
| mesh[19].descriptor_ui | D001921 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | metabolism |
| mesh[19].descriptor_name | Brain |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D006801 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Humans |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D000818 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Animals |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D000097789 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Glucagon-Like Peptide-1 Receptor Agonists |
| mesh[23].qualifier_ui | Q000378 |
| mesh[23].descriptor_ui | D000067757 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | metabolism |
| mesh[23].descriptor_name | Glucagon-Like Peptide-1 Receptor |
| mesh[24].qualifier_ui | Q000627 |
| mesh[24].descriptor_ui | D018696 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | therapeutic use |
| mesh[24].descriptor_name | Neuroprotective Agents |
| mesh[25].qualifier_ui | Q000494 |
| mesh[25].descriptor_ui | D018696 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | pharmacology |
| mesh[25].descriptor_name | Neuroprotective Agents |
| mesh[26].qualifier_ui | Q000188 |
| mesh[26].descriptor_ui | D009422 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | drug therapy |
| mesh[26].descriptor_name | Nervous System Diseases |
| mesh[27].qualifier_ui | Q000378 |
| mesh[27].descriptor_ui | D009422 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | metabolism |
| mesh[27].descriptor_name | Nervous System Diseases |
| mesh[28].qualifier_ui | Q000187 |
| mesh[28].descriptor_ui | D001921 |
| mesh[28].is_major_topic | True |
| mesh[28].qualifier_name | drug effects |
| mesh[28].descriptor_name | Brain |
| mesh[29].qualifier_ui | Q000378 |
| mesh[29].descriptor_ui | D001921 |
| mesh[29].is_major_topic | True |
| mesh[29].qualifier_name | metabolism |
| mesh[29].descriptor_name | Brain |
| type | review |
| title | From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics |
| biblio.issue | 5 |
| biblio.volume | 22 |
| biblio.last_page | e00712 |
| biblio.first_page | e00712 |
| topics[0].id | https://openalex.org/T10401 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2712 |
| topics[0].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[0].display_name | Diabetes Treatment and Management |
| topics[1].id | https://openalex.org/T12267 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9997000098228455 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2737 |
| topics[1].subfield.display_name | Physiology |
| topics[1].display_name | Diet and metabolism studies |
| topics[2].id | https://openalex.org/T11339 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9987999796867371 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1312 |
| topics[2].subfield.display_name | Molecular Biology |
| topics[2].display_name | Metabolism, Diabetes, and Cancer |
| is_xpac | False |
| apc_list.value | 3890 |
| apc_list.currency | EUR |
| apc_list.value_usd | 4990 |
| apc_paid.value | 3890 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 4990 |
| concepts[0].id | https://openalex.org/C16568411 |
| concepts[0].level | 2 |
| concepts[0].score | 0.5352286696434021 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q83042 |
| concepts[0].display_name | Neurology |
| concepts[1].id | https://openalex.org/C169760540 |
| concepts[1].level | 1 |
| concepts[1].score | 0.5195693969726562 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q207011 |
| concepts[1].display_name | Neuroscience |
| concepts[2].id | https://openalex.org/C62231903 |
| concepts[2].level | 2 |
| concepts[2].score | 0.5188851952552795 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1057 |
| concepts[2].display_name | Metabolism |
| concepts[3].id | https://openalex.org/C170493617 |
| concepts[3].level | 2 |
| concepts[3].score | 0.4943835735321045 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[3].display_name | Receptor |
| concepts[4].id | https://openalex.org/C185592680 |
| concepts[4].level | 0 |
| concepts[4].score | 0.3525036573410034 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[4].display_name | Chemistry |
| concepts[5].id | https://openalex.org/C86803240 |
| concepts[5].level | 0 |
| concepts[5].score | 0.33180129528045654 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[5].display_name | Biology |
| concepts[6].id | https://openalex.org/C55493867 |
| concepts[6].level | 1 |
| concepts[6].score | 0.286367803812027 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[6].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/neurology |
| keywords[0].score | 0.5352286696434021 |
| keywords[0].display_name | Neurology |
| keywords[1].id | https://openalex.org/keywords/neuroscience |
| keywords[1].score | 0.5195693969726562 |
| keywords[1].display_name | Neuroscience |
| keywords[2].id | https://openalex.org/keywords/metabolism |
| keywords[2].score | 0.5188851952552795 |
| keywords[2].display_name | Metabolism |
| keywords[3].id | https://openalex.org/keywords/receptor |
| keywords[3].score | 0.4943835735321045 |
| keywords[3].display_name | Receptor |
| keywords[4].id | https://openalex.org/keywords/chemistry |
| keywords[4].score | 0.3525036573410034 |
| keywords[4].display_name | Chemistry |
| keywords[5].id | https://openalex.org/keywords/biology |
| keywords[5].score | 0.33180129528045654 |
| keywords[5].display_name | Biology |
| keywords[6].id | https://openalex.org/keywords/biochemistry |
| keywords[6].score | 0.286367803812027 |
| keywords[6].display_name | Biochemistry |
| language | en |
| locations[0].id | doi:10.1016/j.neurot.2025.e00712 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S75519821 |
| locations[0].source.issn | 1878-7479, 1933-7213 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1878-7479 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Neurotherapeutics |
| locations[0].source.host_organization | https://openalex.org/P4310319900 |
| locations[0].source.host_organization_name | Springer Science+Business Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319900, https://openalex.org/P4310319965 |
| locations[0].source.host_organization_lineage_names | Springer Science+Business Media, Springer Nature |
| locations[0].license | |
| locations[0].pdf_url | https://www.neurotherapeuticsjournal.org/article/S1878-7479(25)00190-4/pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Neurotherapeutics |
| locations[0].landing_page_url | https://doi.org/10.1016/j.neurot.2025.e00712 |
| locations[1].id | pmid:40738791 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40738791 |
| locations[2].id | pmh:oai:doaj.org/article:3e597eb5de7b483493de292c3397a338 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Neurotherapeutics, Vol 22, Iss 5, Pp e00712- (2025) |
| locations[2].landing_page_url | https://doaj.org/article/3e597eb5de7b483493de292c3397a338 |
| locations[3].id | pmh:oai:europepmc.org:11302275 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306400806 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Europe PMC (PubMed Central) |
| locations[3].source.host_organization | https://openalex.org/I1303153112 |
| locations[3].source.host_organization_name | European Bioinformatics Institute |
| locations[3].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12491786 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5067592317 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-2726-4845 |
| authorships[0].author.display_name | Akash Roy |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I145311948, https://openalex.org/I2799853436 |
| authorships[0].affiliations[0].raw_affiliation_string | Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA. |
| authorships[0].institutions[0].id | https://openalex.org/I2799853436 |
| authorships[0].institutions[0].ror | https://ror.org/037zgn354 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I2799853436 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Johns Hopkins Medicine |
| authorships[0].institutions[1].id | https://openalex.org/I145311948 |
| authorships[0].institutions[1].ror | https://ror.org/00za53h95 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I145311948 |
| authorships[0].institutions[1].country_code | US |
| authorships[0].institutions[1].display_name | Johns Hopkins University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Akash Roy |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA. |
| authorships[1].author.id | https://openalex.org/A5025568267 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-2915-3970 |
| authorships[1].author.display_name | Valina L. Dawson |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I145311948, https://openalex.org/I2799853436 |
| authorships[1].affiliations[0].raw_affiliation_string | Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Physiology, Pharmacology and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: [email protected]. |
| authorships[1].institutions[0].id | https://openalex.org/I2799853436 |
| authorships[1].institutions[0].ror | https://ror.org/037zgn354 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I2799853436 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Johns Hopkins Medicine |
| authorships[1].institutions[1].id | https://openalex.org/I145311948 |
| authorships[1].institutions[1].ror | https://ror.org/00za53h95 |
| authorships[1].institutions[1].type | education |
| authorships[1].institutions[1].lineage | https://openalex.org/I145311948 |
| authorships[1].institutions[1].country_code | US |
| authorships[1].institutions[1].display_name | Johns Hopkins University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Valina L. Dawson |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Physiology, Pharmacology and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: [email protected]. |
| authorships[2].author.id | https://openalex.org/A5021759485 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-6459-0893 |
| authorships[2].author.display_name | Ted M. Dawson |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I145311948, https://openalex.org/I2799853436 |
| authorships[2].affiliations[0].raw_affiliation_string | Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Physiology, Pharmacology and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: [email protected]. |
| authorships[2].institutions[0].id | https://openalex.org/I2799853436 |
| authorships[2].institutions[0].ror | https://ror.org/037zgn354 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I2799853436 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Johns Hopkins Medicine |
| authorships[2].institutions[1].id | https://openalex.org/I145311948 |
| authorships[2].institutions[1].ror | https://ror.org/00za53h95 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I145311948 |
| authorships[2].institutions[1].country_code | US |
| authorships[2].institutions[1].display_name | Johns Hopkins University |
| authorships[2].author_position | last |
| authorships[2].raw_author_name | Ted M. Dawson |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Physiology, Pharmacology and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: [email protected]. |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.neurotherapeuticsjournal.org/article/S1878-7479(25)00190-4/pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10401 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2712 |
| primary_topic.subfield.display_name | Endocrinology, Diabetes and Metabolism |
| primary_topic.display_name | Diabetes Treatment and Management |
| related_works | https://openalex.org/W4391375266, https://openalex.org/W2082860237, https://openalex.org/W2119695867, https://openalex.org/W2130076355, https://openalex.org/W1990804418, https://openalex.org/W1993764875, https://openalex.org/W2046158694, https://openalex.org/W2788277189, https://openalex.org/W2013243191, https://openalex.org/W1971568933 |
| cited_by_count | 5 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 5 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1016/j.neurot.2025.e00712 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S75519821 |
| best_oa_location.source.issn | 1878-7479, 1933-7213 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1878-7479 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Neurotherapeutics |
| best_oa_location.source.host_organization | https://openalex.org/P4310319900 |
| best_oa_location.source.host_organization_name | Springer Science+Business Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319900, https://openalex.org/P4310319965 |
| best_oa_location.source.host_organization_lineage_names | Springer Science+Business Media, Springer Nature |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://www.neurotherapeuticsjournal.org/article/S1878-7479(25)00190-4/pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Neurotherapeutics |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.neurot.2025.e00712 |
| primary_location.id | doi:10.1016/j.neurot.2025.e00712 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S75519821 |
| primary_location.source.issn | 1878-7479, 1933-7213 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1878-7479 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Neurotherapeutics |
| primary_location.source.host_organization | https://openalex.org/P4310319900 |
| primary_location.source.host_organization_name | Springer Science+Business Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319900, https://openalex.org/P4310319965 |
| primary_location.source.host_organization_lineage_names | Springer Science+Business Media, Springer Nature |
| primary_location.license | |
| primary_location.pdf_url | https://www.neurotherapeuticsjournal.org/article/S1878-7479(25)00190-4/pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Neurotherapeutics |
| primary_location.landing_page_url | https://doi.org/10.1016/j.neurot.2025.e00712 |
| publication_date | 2025-07-29 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W2106036385, https://openalex.org/W2791728731, https://openalex.org/W2795481136, https://openalex.org/W1967442749, https://openalex.org/W2084948079, https://openalex.org/W3177122952, https://openalex.org/W2978840913, https://openalex.org/W3127371223, https://openalex.org/W3089728969, https://openalex.org/W3184607597, https://openalex.org/W2090147204, https://openalex.org/W2054687207, https://openalex.org/W2111749961, https://openalex.org/W2001808016, https://openalex.org/W4252795044, https://openalex.org/W2148594052, https://openalex.org/W2996954386, https://openalex.org/W3199865840, https://openalex.org/W3096746160, https://openalex.org/W4407549600, https://openalex.org/W4386274913, https://openalex.org/W4220932880, https://openalex.org/W2063298178, https://openalex.org/W3163541922, https://openalex.org/W4294162864, https://openalex.org/W1601982370, https://openalex.org/W2171250577, https://openalex.org/W344771105, https://openalex.org/W2148456968, https://openalex.org/W2152355721, https://openalex.org/W6738808965, https://openalex.org/W4406156729, https://openalex.org/W2342553225, https://openalex.org/W4379985260, https://openalex.org/W2785903681, https://openalex.org/W3157204291, https://openalex.org/W4221041575, https://openalex.org/W4403703331, https://openalex.org/W2093352420, https://openalex.org/W2123319002, https://openalex.org/W2744843428, https://openalex.org/W4393950379, https://openalex.org/W4393852482, https://openalex.org/W4396915280, https://openalex.org/W4389657185, https://openalex.org/W3180369792, https://openalex.org/W4405357489, https://openalex.org/W4390475387, https://openalex.org/W4283460245, https://openalex.org/W4396705969, https://openalex.org/W3193716349, https://openalex.org/W2807256450, https://openalex.org/W2030270894, https://openalex.org/W4389799894, https://openalex.org/W4409119298, https://openalex.org/W4286631403, https://openalex.org/W2005474341, https://openalex.org/W4206445899, https://openalex.org/W2013082477, https://openalex.org/W4323294418, https://openalex.org/W2465339739, https://openalex.org/W2514294108, https://openalex.org/W2425644022, https://openalex.org/W4309438512, https://openalex.org/W3164214667, https://openalex.org/W4226184227 |
| referenced_works_count | 66 |
| abstract_inverted_index.a | 18 |
| abstract_inverted_index.as | 83 |
| abstract_inverted_index.in | 17, 30, 34, 50, 74, 103, 108 |
| abstract_inverted_index.of | 20, 52, 131 |
| abstract_inverted_index.to | 72, 90, 134 |
| abstract_inverted_index.and | 8, 36, 41, 59, 77, 85, 96, 114, 127 |
| abstract_inverted_index.are | 10, 27, 87, 100 |
| abstract_inverted_index.for | 6, 14 |
| abstract_inverted_index.now | 11 |
| abstract_inverted_index.the | 129 |
| abstract_inverted_index.use | 107, 130 |
| abstract_inverted_index.been | 68 |
| abstract_inverted_index.have | 67 |
| abstract_inverted_index.safe | 102 |
| abstract_inverted_index.such | 82 |
| abstract_inverted_index.GLP-1 | 0 |
| abstract_inverted_index.NLY01 | 84 |
| abstract_inverted_index.Newer | 80 |
| abstract_inverted_index.These | 23 |
| abstract_inverted_index.While | 44 |
| abstract_inverted_index.brain | 31 |
| abstract_inverted_index.owing | 71 |
| abstract_inverted_index.range | 19 |
| abstract_inverted_index.study | 75 |
| abstract_inverted_index.their | 106 |
| abstract_inverted_index.trial | 65, 78 |
| abstract_inverted_index.under | 12, 88 |
| abstract_inverted_index.whose | 25 |
| abstract_inverted_index.(ALS), | 63 |
| abstract_inverted_index.Future | 117 |
| abstract_inverted_index.models | 51 |
| abstract_inverted_index.system | 94 |
| abstract_inverted_index.widely | 28 |
| abstract_inverted_index.agents, | 24, 81 |
| abstract_inverted_index.careful | 112 |
| abstract_inverted_index.central | 92 |
| abstract_inverted_index.design. | 79 |
| abstract_inverted_index.effects | 16 |
| abstract_inverted_index.enhance | 91 |
| abstract_inverted_index.include | 119 |
| abstract_inverted_index.largely | 70 |
| abstract_inverted_index.lateral | 61 |
| abstract_inverted_index.nervous | 93 |
| abstract_inverted_index.patient | 115 |
| abstract_inverted_index.promote | 42 |
| abstract_inverted_index.regions | 32 |
| abstract_inverted_index.release | 40 |
| abstract_inverted_index.studies | 46 |
| abstract_inverted_index.Although | 98 |
| abstract_inverted_index.GLP-1RAs | 99 |
| abstract_inverted_index.agonists | 2 |
| abstract_inverted_index.approved | 5 |
| abstract_inverted_index.benefits | 49 |
| abstract_inverted_index.clinical | 64 |
| abstract_inverted_index.diabetes | 7 |
| abstract_inverted_index.disease, | 54, 56 |
| abstract_inverted_index.diseases | 110 |
| abstract_inverted_index.involved | 33 |
| abstract_inverted_index.maximize | 135 |
| abstract_inverted_index.medicine | 125 |
| abstract_inverted_index.modulate | 38 |
| abstract_inverted_index.multiple | 57 |
| abstract_inverted_index.obesity, | 9 |
| abstract_inverted_index.outcomes | 66 |
| abstract_inverted_index.receptor | 1 |
| abstract_inverted_index.reliable | 121 |
| abstract_inverted_index.requires | 111 |
| abstract_inverted_index.cognition | 35 |
| abstract_inverted_index.efficacy. | 97 |
| abstract_inverted_index.exploring | 128 |
| abstract_inverted_index.expressed | 29 |
| abstract_inverted_index.generally | 101 |
| abstract_inverted_index.initially | 4 |
| abstract_inverted_index.metabolic | 104 |
| abstract_inverted_index.precision | 124 |
| abstract_inverted_index.receptors | 26 |
| abstract_inverted_index.sclerosis | 62 |
| abstract_inverted_index.therapies | 133 |
| abstract_inverted_index.variable, | 69 |
| abstract_inverted_index.developing | 120 |
| abstract_inverted_index.directions | 118 |
| abstract_inverted_index.disorders. | 22 |
| abstract_inverted_index.monitoring | 113 |
| abstract_inverted_index.potential. | 137 |
| abstract_inverted_index.sclerosis, | 58 |
| abstract_inverted_index.selection. | 116 |
| abstract_inverted_index.(GLP-1RAs), | 3 |
| abstract_inverted_index.Alzheimer's | 53 |
| abstract_inverted_index.Parkinson's | 55 |
| abstract_inverted_index.amyotrophic | 60 |
| abstract_inverted_index.biomarkers, | 122 |
| abstract_inverted_index.combination | 132 |
| abstract_inverted_index.conditions, | 105 |
| abstract_inverted_index.demonstrate | 48 |
| abstract_inverted_index.development | 89 |
| abstract_inverted_index.metabolism, | 37 |
| abstract_inverted_index.penetration | 95 |
| abstract_inverted_index.populations | 76 |
| abstract_inverted_index.preclinical | 45 |
| abstract_inverted_index.strategies, | 126 |
| abstract_inverted_index.therapeutic | 136 |
| abstract_inverted_index.consistently | 47 |
| abstract_inverted_index.implementing | 123 |
| abstract_inverted_index.neurological | 21, 109 |
| abstract_inverted_index.tirzepatide, | 86 |
| abstract_inverted_index.heterogeneity | 73 |
| abstract_inverted_index.investigation | 13 |
| abstract_inverted_index.neurogenesis. | 43 |
| abstract_inverted_index.neuroprotective | 15 |
| abstract_inverted_index.neurotransmitter | 39 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 97 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 3 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/2 |
| sustainable_development_goals[0].score | 0.699999988079071 |
| sustainable_development_goals[0].display_name | Zero hunger |
| citation_normalized_percentile.value | 0.98467547 |
| citation_normalized_percentile.is_in_top_1_percent | True |
| citation_normalized_percentile.is_in_top_10_percent | True |